In a report published on Friday, Jefferies analyst Biren Amin downgraded Onyx Pharmaceuticals ONXX from Buy to Hold and raised the price target on the company from $104 to $132.
In the report, Jefferies stated, "Given the M&A interest in ONXX we are downgrading to Hold on valuation and raising our PT to $132 (v. $104 prev), which incorporates a lower discount rate to reflect the potential M&A transaction and also includes outer year royalties from palbociclib. We believe upside from current valuation may be limited given the likelihood of a transaction closing between ~$140-145/share."
Onyx Pharmaceuticals closed on Thursday at $134.40.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.